Cizzle Biotechnology Holdings PLC (GB:CIZ)
LSE:CIZ
Want to see GB:CIZ full AI Analyst Report?
CIZ Stock Chart & Stats
1.55 p
<0.01 p(0.26%)
At close: 4:00 PM EST
1.55 p
<0.01 p(0.26%)
Day’s Range― - ―
52-Week Range1.20 p - 3.90 p
Previous CloseN/A
Volume291.66K
Average Volume (3M)1.23M
Market Cap
£12.54M
Enterprise Value12.42M
Total Cash (Recent Filing)£116.00K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta-0.45
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding424,963,200
10 Day Avg. Volume655,017
30 Day Avg. Volume1,232,506
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-18.07
Price to Sales (P/S)0.00
P/FCF Ratio-12.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Reported LeverageLow reported debt materially reduces bankruptcy and interest-rate risk, giving management more optionality on timing of financing and development milestones. For a pre-revenue biotech, minimal leverage preserves flexibility for dilutive equity raises or milestone-based partnerships over the next 2–6 months.
Targeting Early Lung Cancer DiagnosticsA clear strategic focus on blood-based early-detection lung cancer tests aligns with durable structural demand for non-invasive diagnostics and earlier intervention. If validation succeeds, this market positioning supports repeatable commercialization pathways and high long-term clinical need.
Cash Flow Transparency (FCF ≈ Net Income)FCF closely tracking net income indicates accounting losses largely convert to real cash outflows, improving forecastability of financing needs. This transparency helps model burn and capital requirements, aiding durable planning for clinical development and fundraising timing.
Bears Say
Pre-revenue With Persistent LossesBeing pre-revenue with recurring operating losses means the business cannot self-fund development. Over a multi-month horizon this creates structural dependence on external capital or partnerships before any commercial validation can monetize the technology.
Eroding Equity And Shrinking Asset BaseNegative equity and sharply lower assets reflect cumulative losses that weaken borrowing capacity and reduce financial resilience. This structural deterioration increases the likelihood of dilutive financings or constrained strategic choices over the next several months.
Consistent Negative Operating And Free Cash FlowSustained negative operating and free cash flow necessitate regular external funding to continue R&D and validation programs. Given the small asset base and no revenues, this creates an ongoing structural funding risk and potential for repeated dilution until commercialization.
Cizzle Biotechnology Holdings PLC News
CIZ FAQ
What was Cizzle Biotechnology Holdings PLC’s price range in the past 12 months?
Cizzle Biotechnology Holdings PLC lowest share price was 1.20 p and its highest was 3.90 p in the past 12 months.
What is Cizzle Biotechnology Holdings PLC’s market cap?
Cizzle Biotechnology Holdings PLC’s market cap is £12.54M.
When is Cizzle Biotechnology Holdings PLC’s upcoming earnings report date?
Cizzle Biotechnology Holdings PLC’s upcoming earnings report date is Sep 24, 2026 which is in 106 days.
How were Cizzle Biotechnology Holdings PLC’s earnings last quarter?
Cizzle Biotechnology Holdings PLC released its earnings results on Apr 30, 2026. The company reported -0.001 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001 p.
Is Cizzle Biotechnology Holdings PLC overvalued?
According to Wall Street analysts Cizzle Biotechnology Holdings PLC’s price is currently Overvalued.
Does Cizzle Biotechnology Holdings PLC pay dividends?
Cizzle Biotechnology Holdings PLC does not currently pay dividends.
What is Cizzle Biotechnology Holdings PLC’s EPS estimate?
Cizzle Biotechnology Holdings PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cizzle Biotechnology Holdings PLC have?
Cizzle Biotechnology Holdings PLC has 424,963,200 shares outstanding.
What happened to Cizzle Biotechnology Holdings PLC’s price movement after its last earnings report?
Cizzle Biotechnology Holdings PLC reported an EPS of -0.001 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.636%.
Which hedge fund is a major shareholder of Cizzle Biotechnology Holdings PLC?
Currently, no hedge funds are holding shares in GB:CIZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings Plc specializes in developing an advanced immunoassay diagnostic test. This innovative tool aims to identify the CIZ1B biomarker, facilitating the early detection of lung cancer. The company, previously known as Cizzle Biotechnology Limited, officially changed its corporate identity to Cizzle Biotechnology Holdings Plc in May 2021. Its main operational base is situated in London, United Kingdom.